Company intelligence / Profile preview

Palleon Pharmaceuticals

Waltham, Massachusetts, United Statespalleonpharma.com ↗

Ownership: Private
Employees: ~75
Development stage: Preclinical

Overview

Palleon's lead candidate E‑602 has demonstrated proof of mechanism and dose-dependent immune activation as a monotherapy in the GLIMMER‑01 trial for solid tumors. The drug was well tolerated with no dose-limiting toxicities. E‑602 has advanced to Phase 2 trials for autoimmune diseases under a collaboration with Henlius. The company’s platforms enable novel glyco-immunology approaches to address resistance to first-generation immuno-oncology drugs and expand treatment options across cancer and autoimmunity

Therapeutic areas: OncologyImmunology
Modalities: Enzyme-antibody fusion proteins (glycan editing enzymes)Glycoimmune checkpoint inhibitors
Industry: Biotech

Drug pipeline

7 assets

efgitasialase alfa

6 more assets in the full pipeline.

Request access →

Partnerships

Henlius – collaboration on clinical development of E‑602 for autoimmune diseasePfizer Ventures – strategic investor with board representation

Beyond the preview

Go deeper on Palleon Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Palleon Pharmaceuticals.

Explore the full profile